How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

被引：28

作者：

Ferretti, Francesca ^{[1
]}

Cannatelli, Rosanna ^{[1
]}

Benucci, Maurizio ^{[2
]}

Carmagnola, Stefania ^{[1
]}

Clementi, Emilio ^{[3
,4
]}

Danelli, Piergiorgio ^{[5
]}

Dilillo, Dario ^{[6
]}

Fiorina, Paolo ^{[7
,8
,9
]}

Galli, Massimo ^{[10
]}

Gallieni, Maurizio ^{[11
,12
]}

Genovese, Giovanni ^{[1
,13
,14
]}

Giorgi, Valeria ^{[15
]}

Invernizzi, Alessandro ^{[16
,17
]}

Maconi, Giovanni ^{[1
]}

Maier, Jeanette A. ^{[11
]}

Marzano, Angelo V. ^{[14
]}

Morpurgo, Paola S. ^{[7
]}

Nebuloni, Manuela ^{[18
]}

Radovanovic, Dejan ^{[19
]}

Riva, Agostino ^{[11
]}

Rizzardini, Giuliano ^{[20
,21
]}

Sabiu, Gianmarco ^{[11
]}

Santus, Pierachille ^{[11
,19
]}

Staurenghi, Giovanni ^{[16
]}

Zuccotti, Gianvincenzo ^{[6
]}

Sarzi-Puttini, Pier Carlo ^{[15
]}

Ardizzone, Sandro ^{[1
]}

机构：

[1] Univ Milan, Dept Biomed & Clin Sci DIBIC L Sacco, Gastroenterol Unit, ASST Fatebenefratelli Sacco, Milan, Italy

[2] S Giovanni Dio Hosp, Rheumatol Unit, Azienda USL Toscana Ctr, Florence, Italy

[3] Univ Milan, Dept Biomed & Clin Sci DIBIC L Sacco, Unit Clin Pharmacol, Milan, Italy

[4] Sci Inst IRCCS E Medea, Lecce, Italy

[5] Univ Milan, Dept Biomed & Clin Sci DIBIC L Sacco, Surg Unit, ASST Fatebenefratelli Sacco, Milan, Italy

[6] Univ Milan, Pediat Dept, Dept Biomed & Clin Sci DIBIC L Sacco, Osped Bambini,ASST Fatebenefratelli Sacco, Milan, Italy

[7] ASST Fatebenefratelli Sacco, Div Endocrinol, Milan, Italy

[8] Univ Milan, Int Ctr T1D, Pediat Clin Res Ctr Romeo & Enrica Invernizzi, DIBIC, Milan, Italy

[9] Harvard Med Sch, Boston Childrens Hosp, Nephrol Div, Boston, MA 02115 USA

[10] Univ Milan, Univ Hosp Luigi Sacco, Dept Biomed & Clin Sci DIBIC L Sacco, Infect Dis Unit 3, Milan, Italy

[11] Univ Milan, Dept Biomed & Clin Sci DIBIC L Sacco, Milan, Italy

[12] L Sacco Hosp Vialba, Nephrol & Dialysis Unit, ASST Fatebenefratelli Sacco, Milan, Italy

[13] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[14] Univ Milan, Dermatol Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[15] Univ Milan, Dept Biomed & Clin Sci DIBIC L Sacco, Rheumatol Unit, Milan, Italy

[16] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy

[17] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia

[18] Univ Milan, Dept Biomed & Clin Sci DIBIC L Sacco, Pathol Unit, Milan, Italy

[19] Osped L Sacco, Div Resp Dis, ASST Fatebenefratelli Sacco, Milan, Italy

[20] Univ Milan, Dept Infect Dis, ASST Fatebenefratelli Sacco, Milan, Italy

[21] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Johannesburg, South Africa

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

关键词：

COVID-19; Sars-CoV-2; vaccine; IMIDs; chronic disease; prevention; EFFICACY; RISK;

D O I：

10.3389/fimmu.2021.656362

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.

引用

页数：14

共 50 条

[41] Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination
Picod, Adrien
Rebibou, Jean-Michel
Dossier, Antoine
Cador, Berengere
Ribes, David
Vasco-Moynet, Claire
Stephan, Caroline
Bellal, Mathieu
Wynckel, Alain
Poullin, Pascale
Peju, Edwige
Ricard, Laure
Kahn, Jean-Emmanuel
Bouzid, Raida
Benhamou, Ygal
Joly, Berangere
Veyradier, Agnes
Coppo, Paul
BLOOD, 2022, 139 (16) : 2565 - +
[42] Risk of post-acute sequalae of COVID-19 in patients with immune-mediated inflammatory diseases
Vitus, E. S.
Sorensen, C. N.
Sandri, A. K.
Elmahdi, R.
Jess, T.
JOURNAL OF CROHNS & COLITIS, 2025, 19
[43] IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES TAKING A BIOLOGIC THERAPY
Halioua, B.
Zetlaoui, J.
Astruc, A.
Testa, D.
Bombezin-Domino, A.
Radoszycki, L.
VALUE IN HEALTH, 2020, 23 : S622 - S622
[44] National Survey on Patient's Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
Goulenok, Tiphaine
Mageau, Arthur
Francois, Chrystelle
Hachulla, Eric
Papo, Thomas
Sacre, Karim
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 508 - 509
[45] How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
Sarzi-Puttini, Piercarlo
Marotto, Daniela
Antivalle, Marco
Salaffi, Fausto
Atzeni, Fabiola
Maconi, Giovanni
Monteleone, Giovanni
Rizzardini, Giuliano
Antinori, Spinello
Galli, Massimo
Ardizzone, Sandro
AUTOIMMUNITY REVIEWS, 2020, 19 (07)
[46] Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic
Fuller, Amy
Hancox, Jennie
Vedhara, Kavita
Card, Tim
Mallen, Christian
Van-Tam, Jonathan S. Nguyen
Abhishek, Abhishek
PLOS ONE, 2022, 17 (09):
[47] Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
Kallinich, Tilmann
Mall, Marcus A.
MOLECULAR AND CELLULAR PEDIATRICS, 2024, 11 (01)
[48] Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
Torres, Tiago
Puig, Luis
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (03) : 307 - 311
[49] COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases
Gauckler, Philipp
Kesenheimer, Jana S.
Geetha, Duvuru
Odler, Balazs
Eller, Kathrin
Laboux, Timothee
Alberici, Federico
Zappa, Mattia
Chebotareva, Natasha
Moiseev, Sergey
Bonilla, Marco
Jhaveri, Kenar D.
Oniszczuk, Julie
Audard, Vincent
Costa, Denise
Mastroianni-Kirsztajn, Gianna
Bruchfeld, Annette
Muto, Masahiro
Windpessl, Martin
Mayer, Gert
Kronbichler, Andreas
FRONTIERS IN IMMUNOLOGY, 2023, 14
[50] Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
Tiago Torres
Luis Puig
American Journal of Clinical Dermatology, 2020, 21 : 307 - 311

← 1 2 3 4 5 →